DK3810201T5 - GIP/GLP1-agonist-sammensætninger - Google Patents

GIP/GLP1-agonist-sammensætninger Download PDF

Info

Publication number
DK3810201T5
DK3810201T5 DK19739766.4T DK19739766T DK3810201T5 DK 3810201 T5 DK3810201 T5 DK 3810201T5 DK 19739766 T DK19739766 T DK 19739766T DK 3810201 T5 DK3810201 T5 DK 3810201T5
Authority
DK
Denmark
Prior art keywords
gip
agonist compositions
glp1 agonist
glp1
compositions
Prior art date
Application number
DK19739766.4T
Other languages
English (en)
Other versions
DK3810201T3 (da
Inventor
Vincent John Corvari
Christopher Sears Minie
Dinesh Shyandeo Mishra
Ken Kangyi Qian
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67263049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3810201(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DK3810201T3 publication Critical patent/DK3810201T3/da
Application granted granted Critical
Publication of DK3810201T5 publication Critical patent/DK3810201T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
DK19739766.4T 2018-06-22 2019-06-14 GIP/GLP1-agonist-sammensætninger DK3810201T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862688632P 2018-06-22 2018-06-22
PCT/US2019/037146 WO2019245893A2 (en) 2018-06-22 2019-06-14 Gip/glp1 agonist compositions

Publications (2)

Publication Number Publication Date
DK3810201T3 DK3810201T3 (da) 2023-06-26
DK3810201T5 true DK3810201T5 (da) 2023-08-21

Family

ID=67263049

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19739766.4T DK3810201T5 (da) 2018-06-22 2019-06-14 GIP/GLP1-agonist-sammensætninger

Country Status (33)

Country Link
US (2) US11357820B2 (da)
EP (2) EP4257185A3 (da)
JP (3) JP6896945B2 (da)
KR (3) KR102523489B1 (da)
CN (1) CN112312926A (da)
AR (1) AR115542A1 (da)
AU (2) AU2019289110B2 (da)
BR (1) BR112020023452A2 (da)
CA (1) CA3103469C (da)
CL (1) CL2020003359A1 (da)
CR (1) CR20200634A (da)
DK (1) DK3810201T5 (da)
EA (1) EA202092713A1 (da)
EC (1) ECSP20082717A (da)
ES (1) ES2953740T3 (da)
FI (1) FI3810201T3 (da)
HR (1) HRP20230748T1 (da)
HU (1) HUE063059T2 (da)
IL (2) IL279504B (da)
JO (1) JOP20200335A1 (da)
LT (1) LT3810201T (da)
MA (1) MA52965B1 (da)
MD (1) MD3810201T2 (da)
MX (1) MX2020013727A (da)
PE (1) PE20210049A1 (da)
PH (1) PH12020552215A1 (da)
PL (1) PL3810201T3 (da)
PT (1) PT3810201T (da)
RS (1) RS64288B9 (da)
SG (1) SG11202012744UA (da)
SI (1) SI3810201T1 (da)
TW (1) TWI705820B (da)
WO (1) WO2019245893A2 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211202A1 (es) 2017-08-24 2021-07-05 Novo Nordisk As Composiciones de glp-1 y sus usos
TWI705820B (zh) * 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
JP2021533094A (ja) * 2018-07-23 2021-12-02 イーライ リリー アンド カンパニー 療法のためｇｉｐ／ｇｌｐ１コアゴニストを使用する方法
KR20210095165A (ko) * 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
JP2022536898A (ja) 2019-06-12 2022-08-22 アスクジーン・ファーマ・インコーポレイテッド 新規ｉｌ－１５プロドラッグおよびその使用方法
CN110642935A (zh) * 2019-09-25 2020-01-03 成都奥达生物科技有限公司 一种替瑞帕肽类似物
WO2021144476A1 (en) 2020-02-18 2021-07-22 Novo Nordisk A/S Pharmaceutical formulations
EP4281464A1 (en) 2021-01-20 2023-11-29 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
CN117866048A (zh) * 2021-05-28 2024-04-12 广东众生睿创生物科技有限公司 多肽的制备及其应用
CN114949183B (zh) * 2022-05-07 2023-02-28 山东京卫制药有限公司 一种替尔泊肽粉雾剂及其制备方法
WO2024006662A1 (en) * 2022-06-30 2024-01-04 Eli Lilly And Company Tirzepatide compositions and use
WO2024061310A1 (zh) * 2022-09-23 2024-03-28 博瑞生物医药（苏州）股份有限公司 一种glp-1和gip双受体激动剂药物组合物及其用途
CN115651075B (zh) * 2022-12-12 2023-04-11 杭州信海医药科技有限公司 一种Tirzepatide的合成方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06247870A (ja) * 1993-02-23 1994-09-06 Ajinomoto Co Inc インターロイキン−６を含有する医薬製剤
NZ250844A (en) 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物
PT1069912E (pt) * 1998-04-03 2007-09-14 Novartis Vaccines & Diagnostic Formulações injectáveis de igf contendo succinato como agente tampão
ATE424413T1 (de) 2000-06-16 2009-03-15 Lilly Co Eli Analoge des glucagon-ähnlichen peptids-1
ES2298378T3 (es) 2001-06-28 2008-05-16 Novo Nordisk A/S Formulacion estable de glp-1 modificado.
JP2007524592A (ja) 2003-06-03 2007-08-30 ノボ・ノルデイスク・エー／エス 安定化された薬学的ペプチド組成物
RU2421238C2 (ru) * 2003-11-20 2011-06-20 Ново Нордиск А/С Пептидная композиция, содержащая пропиленгликоль, являющаяся оптимальной для изготовления и применения в инъекционных устройствах
EP1814581B1 (en) 2004-11-12 2016-03-16 Novo Nordisk A/S Stable formulations of peptides comprising an acylated glp-1 analogue and a basal insuline
DE602005015257D1 (da) 2004-12-22 2009-08-13 Lilly Co Eli
EP1915169A2 (en) * 2005-07-12 2008-04-30 Renovo Limited Pharmaceutical compositions comprising a tgf-beta superfamily member
CN104288756A (zh) * 2006-04-14 2015-01-21 曼金德公司 高血糖素样肽1(glp-1)药物制剂
US8501693B2 (en) 2006-08-04 2013-08-06 Amylin Pharmaceuticals, Llc Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
BRPI0813699B1 (pt) 2007-07-10 2021-06-22 Eli Lilly And Company Formulação de proteína de fusão glp-1-fc
CN101822822A (zh) * 2009-03-04 2010-09-08 北京德众万全药物技术开发有限公司 一种普兰林肽的药物组合物及其制备方法
CA2788304A1 (en) 2010-01-27 2011-08-04 Indiana University Research And Technology Corporation Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
EA027032B1 (ru) 2010-03-01 2017-06-30 Эли Лилли Энд Компани Автоматическое инъекционное устройство с замедлителем, включающим смещающий элемент с двойственной функцией
EP2723367B1 (en) * 2011-06-22 2017-05-03 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
CA2877056A1 (en) 2012-07-01 2014-01-09 Novo Nordisk A/S Use of long-acting glp-1 peptides
AR092862A1 (es) * 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
WO2014081849A1 (en) 2012-11-20 2014-05-30 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
CN103893744B (zh) * 2012-12-24 2017-12-19 杭州九源基因工程有限公司 一种治疗糖尿病的药物制剂及其制备方法
US20160136246A1 (en) 2013-06-21 2016-05-19 Novo Nordisk A/S Novel Uses of GLP-1 Receptor Agonists in Patients Treated with Insulin and/or Suffering from Type 1 Diabetes
CN105451776B (zh) 2013-08-15 2020-04-17 诺和诺德股份有限公司 Glp-1衍生物及其用途
EP3068421B1 (en) 2013-11-15 2019-04-17 Novo Nordisk A/S Selective pyy compounds and uses thereof
US9895424B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
BR112018073511A2 (pt) * 2016-05-16 2019-03-26 Intarcia Therapeutics, Inc. polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
WO2018103868A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物

Also Published As

Publication number Publication date
FI3810201T3 (fi) 2023-08-17
IL279504B (en) 2022-09-01
JP7413315B2 (ja) 2024-01-15
RS64288B1 (sr) 2023-07-31
HRP20230748T1 (hr) 2023-10-27
PL3810201T3 (pl) 2023-09-25
CL2020003359A1 (es) 2021-06-25
WO2019245893A3 (en) 2020-03-12
JP2021506952A (ja) 2021-02-22
BR112020023452A2 (pt) 2021-02-23
AU2022279524A1 (en) 2023-02-02
AU2019289110B2 (en) 2022-10-06
EP3810201A2 (en) 2021-04-28
RS64288B9 (sr) 2023-11-30
IL295433A (en) 2022-10-01
AU2019289110A1 (en) 2021-01-21
IL279504A (en) 2021-01-31
JP6896945B2 (ja) 2021-06-30
TWI705820B (zh) 2020-10-01
SI3810201T1 (sl) 2023-08-31
JP2024041808A (ja) 2024-03-27
MD3810201T2 (ro) 2023-11-30
PT3810201T (pt) 2023-07-04
MX2020013727A (es) 2021-03-02
ES2953740T3 (es) 2023-11-15
AR115542A1 (es) 2021-01-27
PE20210049A1 (es) 2021-01-08
US11918623B2 (en) 2024-03-05
SG11202012744UA (en) 2021-01-28
WO2019245893A2 (en) 2019-12-26
US20220273762A1 (en) 2022-09-01
EP3810201B1 (en) 2023-06-07
PH12020552215A1 (en) 2021-06-28
DK3810201T3 (da) 2023-06-26
JOP20200335A1 (ar) 2020-12-20
JP2021167314A (ja) 2021-10-21
EA202092713A1 (ru) 2021-04-05
KR102523489B1 (ko) 2023-04-21
CR20200634A (es) 2021-01-21
MA52965B1 (fr) 2023-08-31
CA3103469C (en) 2024-04-09
KR20210010572A (ko) 2021-01-27
MA52965A (fr) 2021-04-28
EP3810201B9 (en) 2023-08-02
LT3810201T (lt) 2023-07-25
IL295433B1 (en) 2023-11-01
ECSP20082717A (es) 2021-01-29
TW202015717A (zh) 2020-05-01
US20190388502A1 (en) 2019-12-26
CA3103469A1 (en) 2019-12-26
CN112312926A (zh) 2021-02-02
HUE063059T2 (hu) 2023-12-28
EP4257185A3 (en) 2024-01-17
EP4257185A2 (en) 2023-10-11
KR20230058172A (ko) 2023-05-02
US11357820B2 (en) 2022-06-14
KR20240060873A (ko) 2024-05-08
IL295433B2 (en) 2024-03-01

Similar Documents

Publication Publication Date Title
DK3810201T5 (da) GIP/GLP1-agonist-sammensætninger
MA53382A (fr) Composés co-agonistes de gip/glp1
DK3810587T3 (da) Substituerede alkoxypyridinylindolsulfonamider
DK3890488T3 (da) Herbicide sammensætninger
DK3746054T3 (da) Sammensætninger omfattende berberin
DK3591122T3 (da) Hurtigskifter
DK3840596T3 (da) Sammensætning
MA56069A (fr) Composition herbicide
DK3620213T3 (da) Retinololiesammensætning
DK3746047T3 (da) Injektionsbar sammensætning
DK3752258T3 (da) Trampolin
MA52129A (fr) Compositions
MA54534A (fr) Antagonistes
DE112019003235A5 (de) Bauelement
DK3587968T3 (da) Fluidsystem
MA49925A (fr) Claie
DE112019000442A5 (de) Ringtilgereinrichtung
NO20181678A1 (no) Rissanviser
JP1628555S (ja) たい焼
JP1628556S (ja) たい焼
ES1218724Y (es) Terrario
ES1224156Y (es) Ecobolsera
UA38224S (uk) Скребок-різак
UA38131S (uk) Сокира-колун
UA37889S (uk) Молоток-обценьки